Natalizumab increased clinical remission and clinical response in moderate-to-severe Crohn disease
- PMID: 12954036
Natalizumab increased clinical remission and clinical response in moderate-to-severe Crohn disease
Comment on
-
Natalizumab for active Crohn's disease.N Engl J Med. 2003 Jan 2;348(1):24-32. doi: 10.1056/NEJMoa020732. N Engl J Med. 2003. PMID: 12510039 Clinical Trial.